These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 38745461)

  • 1. Hybrid response to SARS-CoV-2 and
    Portilho AI; Hermes Monteiro da Costa H; Grando Guereschi M; Prudencio CR; De Gaspari E
    Hum Vaccin Immunother; 2024 Dec; 20(1):2346963. PubMed ID: 38745461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvants to the S1-subunit of the SARS-CoV-2 spike protein vaccine improve antibody and T cell responses and surrogate neutralization in mice.
    Becker W; Rebbani K; Duan Z; Valkov E; Bryant S; Ho M; Berzofsky JA; Olkhanud PB
    Sci Rep; 2024 Nov; 14(1):29609. PubMed ID: 39609527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccination with outer membrane vesicles from Neisseria Meningitidis and SBa15, SBa16 mesoporous silica associated with SARS-CoV-2 induces protective humoral and cellular response against COVID-19 in mice.
    Bernardes BG; Moura AD; Guarnieri JPO; Silva CFMD; Costa HHMD; Silva IGMD; Cordeiro KBB; Báo SN; Prudêncio CR; Lancellotti M
    Braz J Infect Dis; 2024; 28(6):104479. PubMed ID: 39547005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study.
    Essink BJ; Shapiro C; Isidro MGD; Bradley P; Pragalos A; Bloch M; Santiaguel J; Frias MV; Miyakis S; Alves de Mesquita M; Berrè S; Servais C; Waugh N; Hoffmann C; Baba E; Schönborn-Kellenberger O; Wolz OO; Koch SD; Ganyani T; Boutet P; Mann P; Mueller SO; Ramanathan R; Gaudinski MR; Vanhoutte N
    Hum Vaccin Immunother; 2024 Dec; 20(1):2408863. PubMed ID: 39422261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trimerized S expressed by modified vaccinia virus Ankara (MVA) confers superior protection against lethal SARS-CoV-2 challenge in mice.
    Zhu J; Wang Z; Li Y; Zhang Z; Ren S; Wang J; Xie S; Liao Z; Song B; Wu W; Yan F; Peng C
    J Virol; 2024 Jul; 98(7):e0052124. PubMed ID: 38874361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic characterization and estimated 4CMenB vaccine strain coverage of 284
    Efron A; Brozzi A; Biolchi A; Bodini M; Giuliani M; Guidotti S; Lorenzo F; Moscoloni MA; Muzzi A; Nocita F; Pizza M; Rappuoli R; Tomei S; Vidal G; Vizzotti C; Campos J; Sorhouet Pereira C
    Hum Vaccin Immunother; 2024 Dec; 20(1):2378537. PubMed ID: 39037011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity of intranasal vaccine based on SARS-CoV-2 spike protein during primary and booster immunizations in mice.
    Yang H; Xie Y; Li S; Bao C; Wang J; Li C; Nie J; Quan Y
    Hum Vaccin Immunother; 2024 Dec; 20(1):2364519. PubMed ID: 38880868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial.
    Liu X; Munro APS; Wright A; Feng S; Janani L; Aley PK; Babbage G; Baker J; Baxter D; Bawa T; Bula M; Cathie K; Chatterjee K; Dodd K; Enever Y; Fox L; Qureshi E; Goodman AL; Green CA; Haughney J; Hicks A; Jones CE; Kanji N; van der Klaauw AA; Libri V; Llewelyn MJ; Mansfield R; Maallah M; McGregor AC; Minassian AM; Moore P; Mughal M; Mujadidi YF; Belhadef HT; Holliday K; Osanlou O; Osanlou R; Owens DR; Pacurar M; Palfreeman A; Pan D; Rampling T; Regan K; Saich S; Saralaya D; Sharma S; Sheridan R; Stokes M; Thomson EC; Todd S; Twelves C; Read RC; Charlton S; Hallis B; Ramsay M; Andrews N; Lambe T; Nguyen-Van-Tam JS; Cornelius V; Snape MD; Faust SN;
    J Infect; 2023 Jul; 87(1):18-26. PubMed ID: 37085049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. One dose of COVID-19 nanoparticle vaccine REVC-128 protects against SARS-CoV-2 challenge at two weeks post-immunization.
    Gu M; Torres JL; Li Y; Van Ry A; Greenhouse J; Wallace S; Chiang CI; Pessaint L; Jackson AM; Porto M; Kar S; Li Y; Ward AB; Wang Y
    Emerg Microbes Infect; 2021 Dec; 10(1):2016-2029. PubMed ID: 34651563
    [No Abstract]   [Full Text] [Related]  

  • 10. Recombinant ClearColi™-derived outer membrane vesicles as an effective carrier for development of neoepitope-based vaccine candidate against colon carcinoma.
    Sharif E; Nezafat N; Mohit E
    Int Immunopharmacol; 2024 Dec; 143(Pt 2):113283. PubMed ID: 39418728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of a SARS-CoV-2 recombinant protein subunit vaccine adjuvanted with Alum + CpG 1018 in healthy Indonesian adults: A multicenter, randomized, comparative, observer-blind, placebo-controlled phase 2 study.
    Maddeppungeng M; Nurdin A; Nency YM; Sekartini R; Medise BE; Soedjatmiko S; Massi MN; Darma S; Darussalam AHE; Ramadhani N; Hidayah N; Chalid MT; Ramadany S; Wahyuni S; Djaharuddin I; Santoso A; Fikri B; Alimuddin S; Pelupessy NM; Masadah R; Putri AZ; Setyaningsih L; Yani FF; Anggrainy F; Deza PA; Maharani N; Mahati E; Hapsari R; Farhanah N; Pramudo SG; Tri Anantyo D
    Hum Vaccin Immunother; 2024 Dec; 20(1):2429231. PubMed ID: 39632708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring yeast glucans for vaccine enhancement: Sustainable strategies for overcoming adjuvant challenges in a SARS-CoV-2 model.
    Azevedo-Silva J; Amorim M; Tavares-Valente D; Sousa P; Mohamath R; Voigt EA; Guderian JA; Kinsey R; Viana S; Reis F; Pintado ME; Paddon CJ; Fox CB; Fernandes JC
    Eur J Pharm Biopharm; 2024 Dec; 205():114538. PubMed ID: 39461571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Dual-Adjuvanted Parenteral-Intranasal Subunit Nanovaccine generates Robust Systemic and Mucosal Immunity Against SARS-CoV-2 in Mice.
    Pandey B; Wang Z; Jimenez A; Bhatia E; Jain R; Beach A; Maniar D; Hosten J; O'Farrell L; Vantucci C; Hur D; Noel R; Ringquist R; Smith C; Ochoa MA; Roy K
    Adv Sci (Weinh); 2024 Dec; 11(45):e2402792. PubMed ID: 39352717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical development of SpikoGen®, an Advax-CpG55.2 adjuvanted recombinant spike protein vaccine.
    Petrovsky N
    Hum Vaccin Immunother; 2024 Dec; 20(1):2363016. PubMed ID: 38839044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tackling immunosuppression by Neisseria gonorrhoeae to facilitate vaccine design.
    Jones RA; Ramirez-Bencomo F; Whiting G; Fang M; Lavender H; Kurzyp K; Thistlethwaite A; Stejskal L; Rashmi S; Jerse AE; Cehovin A; Derrick JP; Tang CM
    PLoS Pathog; 2024 Nov; 20(11):e1012688. PubMed ID: 39541395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COVID-19 vaccination survey and anti-SARS-CoV-2 IgG responses in a human cohort from
    Niu M; Mu Y; Adriko M; Candia R; Jones MK; McManus DP; Egwang TG; Cai P
    Front Public Health; 2024; 12():1437063. PubMed ID: 39624416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody response to SARS-CoV-2 mRNA vaccination in Danish adults exposed to perfluoroalkyl substances (PFASs): The ENFORCE study.
    Timmermann A; Johansen IS; Tolstrup M; Heilmann C; Budtz-Jørgensen E; Tolstrup JS; Nielsen F; Grandjean P
    Environ Res; 2024 Dec; 263(Pt 1):120039. PubMed ID: 39326653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Qualitative evidence synthesis informing our understanding of people's perceptions and experiences of targeted digital communication.
    Ryan R; Hill S
    Cochrane Database Syst Rev; 2019 Oct; 10(10):ED000141. PubMed ID: 31643081
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.